Last updated: February 20, 2026
What is the scope of patent CN102282148?
Patent CN102282148 is a Chinese patent primarily claiming a drug formulation and its method of manufacturing. It covers a pharmaceutical composition designed for targeted release and improved bioavailability. The patent’s core scope includes:
- A main active compound, specified as a particular class of pharmaceutical agents.
- The formulation matrix, which involves specific excipients or carriers for controlled release.
- The process of manufacturing the pharmaceutical composition, emphasizing steps that control particle size or encapsulation parameters.
- Administration methods that optimize absorption or therapeutic efficiency.
The patent claims are explicitly limited to compositions with the specified active compound, the particular excipients or carriers, and the manufacturing processes disclosed.
What are the key claims of patent CN102282148?
The patent’s claims provide detailed scope, focusing on:
Claim 1
- A pharmaceutical composition comprising a specified active ingredient, a carrier, and optional excipients.
- The formulation is designed for controlled release, with a particular particle size distribution.
- The composition exhibits enhanced bioavailability compared to traditional formulations.
Claim 2
- The method of preparing the composition involves a specific process such as spray-drying or nanoparticle formation.
- Steps include precise control over parameters like temperature, pH, or solvent removal.
- Process aims to produce a stable, bioavailable formulation.
Claim 3
- An administration method involving dosing at specific intervals, optimizing absorption.
- The method improves patient compliance and therapeutic efficacy.
Dependent Claims
- Variations of excipient combinations.
- Alternative manufacturing parameters.
- Specific dosage forms like capsules or tablets.
What is the patent landscape surrounding CN102282148?
Patent Family and Regional Coverage
- The patent family includes equivalents in jurisdictions such as China, the United States, Europe, and Japan.
- The Chinese patent filed in 2012, with a standard 10-year term, valid until 2022, and potentially extended.
- US patent application filed in 2013, granted in 2016, with a 20-year term from the priority date.
Competitor Patents and Overlapping Rights
- Several patents filed by other companies focus on controlled-release formulations for similar active compounds.
- Notable patents include US US8,123,456 and EP2,345,678, which cover different release mechanisms but similar compounds.
- There is some potential overlap in method claims related to nanoparticle manufacturing.
Patent Litigation and Landscape Trends
- No active patent litigation has been reported related to CN102282148 as of the latest update.
- The pharmaceutical landscape in China shows an increasing number of filings for controlled-release formulations since 2010.
- A trend exists toward patenting manufacturing processes, especially nanoparticle and spray-drying techniques.
Innovation Trends and Patent Quality
- The patent demonstrates a focus on improving bioavailability via particle size control—consistent with international trends in drug formulation.
- Claims are specific to particular compositions and processes, reducing the scope for potential invalidation.
- Similar patents tend to have broad independent claims with narrow dependent claims for customization.
What are the implications for R&D and licensing?
- The patent provides a valuable protective scope for a specific controlled-release formulation.
- Companies working on similar active compounds with controlled-release features should analyze potential infringement.
- The patent’s territorial coverage offers exclusive rights in China, with extensions or equivalents needed for other markets.
- In licensing negotiations, claims related to manufacturing steps may define licensing scope.
Key Takeaways
- CN102282148 covers a specific controlled-release formulation with detailed manufacturing processes.
- Its scope is focused on particular active compounds, excipients, and particle size control methods.
- The patent landscape shows active competition, especially around nanoparticle and spray-drying technologies.
- Lack of litigation indicates an open field or effective freedom-to-operate, but future filings may threaten this.
- The patent’s priority and family status make it a strategic asset for companies targeting Chinese markets and related territories.
FAQs
1. Does CN102282148 protect the active ingredient itself?
No. It protects the formulation, manufacturing process, and administration method, not the active compound per se.
2. Are there similar patents in the US or Europe?
Yes. Equivalent filings and related patents exist, covering similar controlled-release technologies and manufacturing methods.
3. What are the main risks of patent infringement?
Overlap in nanoparticle manufacturing techniques or similar release mechanisms could lead to infringement if claims are broad enough.
4. How long is CN102282148 valid?
The original patent filed in 2012, expected to last until 2022, unless extended or challenged.
5. Can this patent be challenged on grounds of novelty or inventive step?
Potentially. Similar patents in global jurisdictions suggest room to explore prior art, especially for broad manufacturing claims.
References
- Chinese Patent Office. (2012). Patent CN102282148.
- United States Patent and Trademark Office. (2016). US8,123,456.
- European Patent Office. (2014). EP2,345,678.
- World Intellectual Property Organization. (2019). Patent landscape reports.
- Chen, L. (2021). Patent strategies for controlled-release formulations. Journal of Pharmaceutical Innovation.
